Trial NCT02683941

View at ClinicalTrials.gov 
Org. Study IDs: A-US-52030-328
Secondary IDs: 2015-004992-62

Last trial update was posted on 2022-07-06

MeSH Interventions

Lanreotide Somatostatin

MeSH Conditions

Neuroendocrine Tumors

Other Conditions

Neuroendocrine Tumors in Lung

Stopping Reasons

National Comprehensive Cancer Network & European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment.

Limitations And Caveats

The majority of subjects who entered the open-label treatment phase were withdrawn due to study termination by the sponsor.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID